Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.48 |
| ▸ | GJB2 | P29033 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.44 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.44 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.44 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.44 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.43 |
| ▸ | CDC25B | P30305 | 6/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | TACR2 | P21452 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4421768 | 1.00 | NT5E (0.48) | NT5EGJB2SLC6A2SSTR1SSTR2 | |
| SCHEMBL27828449 | 1.00 | NT5E (0.48) | NT5EGJB2SLC6A2SSTR1SSTR2 | |
| SCHEMBL19731779 | 1.00 | NT5E (0.48) | NT5EGJB2SLC6A2SSTR1SSTR2 | |
| SCHEMBL7155844 | 0.93 | GJB2 (0.52) | NT5EGJB2SLC6A2SSTR1SSTR2 | |
| SCHEMBL7567425 | 0.91 | SLC6A2 (0.47) | NT5EGJB2SLC6A2SSTR1SSTR2 | |
| SCHEMBL22683015 | 0.91 | SLC6A2 (0.47) | NT5EGJB2SLC6A2SSTR1SSTR2 | |
| SCHEMBL8708672 | 0.91 | GJB2 (0.52) | NT5EGJB2SLC6A2SSTR1SSTR2 | |
| SCHEMBL20139723 | 0.91 | SLC6A2 (0.47) | NT5EGJB2SLC6A2SSTR1SSTR2 | |
| SCHEMBL7567428 | 0.91 | SLC6A2 (0.47) | NT5EGJB2SLC6A2SSTR1SSTR2 | |
| SCHEMBL6265877 | 0.89 | SSTR1 (0.52) | NT5ESSTR1SSTR2SSTR4SSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160375120-A1 | SYNTHETIC OLIGOSACCHARIDES FOR MORAXELLA VACCINE | VISTERRA INC (US) | 2016-12-29 | — | — | US | disclosed |
| US-9447133-B2 | Synthetic oligosaccharides for moraxella vaccine | Visterra, Inc. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20140148592-A1 | Synthetic Oligosaccharides for Moraxella Vaccine | Visterra, Inc. | 2014-05-29 | — | — | US | disclosed |
| US-8716469-B2 | Synthetic oligosaccharides for Moraxella vaccine | ANCORA PHARMACEUTICALS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130102759-A1 | Synthetic Oligosaccharides for Moraxella Vaccine | SYNGLYCO, INC. | 2013-04-25 | — | — | US | disclosed |
| WO-2011137181-A1 | SYNTHETIC OLIGOSACCHARIDES FOR MORAXELLA VACCINE | ANCORA PHARMACEUTICALS INC. (US) | 2011-11-03 | — | — | WO | disclosed |
| US-7528153-B2 | Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors | GENZYME CORPORATION (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070066581-A1 | Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors | GENZYME CORPORATION | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066581-A1 | Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors | GAA, GBA1, GBA3 | NT5E 795/4885GJB2 4880/4885SLC6A2 1384/4885 |
| US-20160375120-A1 | SYNTHETIC OLIGOSACCHARIDES FOR MORAXELLA VACCINE | FUT6, FUT5, MGAM | NT5E 2374/4885GJB2 3838/4885SLC6A2 4840/4885 |
| US-20130102759-A1 | Synthetic Oligosaccharides for Moraxella Vaccine | FUT6, OSTC, MGAM | NT5E 2680/4885GJB2 3868/4885SLC6A2 4837/4885 |
| US-20140148592-A1 | Synthetic Oligosaccharides for Moraxella Vaccine | FUT6, FUT5, MGAM | NT5E 2374/4885GJB2 3838/4885SLC6A2 4840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.